Abstract: The invention relates to novel 1-oxaspiro[2,5]octan-6-ol derivatives of general formula (I):
and also to a method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine, or in cosmetic compositions.
Abstract: The invention relates to novel bicyclic compounds having the general formula (I):
as well as to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, in carcinology and in the field of autoimmune diseases and that of organ or tissue transplants in particular), or alternatively in cosmetic compositions.
Abstract: The invention concerns novel bi-aromatic compounds having the formula:
which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.
Abstract: The present invention relates to pharmaceutical and cosmetic compositions comprising at least one agonist ligand, which is specific for receptors of the RAR-&ggr; type, which are characterized as inducers of apoptosis in at least one cell population in which apoptosis can be induced by activating receptors of the RAR-&ggr; type. In one aspect of the present invention, there is provided a method of combating photoinduced or chronological ageing of skin, said method comprising administering an effective amount of at least one agonist ligand which is specific for receptors of the RAR-&ggr; type to combat photoinduced or chronological aging of skin, wherein the agonist ligand has a ratio R which is equal to or greater than 10.
Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I):
in which Ar1 is a radical having one of the structural formulae (a)-(c):
Ar2 is a radical having one of the following formulae (d)-(h):
and X is a radical having one of the following formulae (i)-(l):
and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Abstract: An in vitro assay for selecting compounds that alter pigmentation of skin is provided. Also, a novel class of pro-pigmentatory compounds is provided which comprise substituted aromatic or heterocyclic carboxylic acids, or derivatives thereof, or pharmaceutically acceptable salts, which do not contain a pheno, naphthol, thiophenol, or a thionaphthol function in free or protected form. In a preferred embodiment, thess compounds will display activity for RXRs. These compounds may be used for altering pigmentation of human skin and/or hair in cosmetic or dermatological compositions, and for the treatment of disorders and disease conditions that affect skin or hair pigmentation.
Type:
Application
Filed:
January 17, 2003
Publication date:
June 19, 2003
Applicant:
Galderma Research & Development, S.N.C.
Abstract: The apparatus for uniting the lips of a wound comprises a laser having an emission wavelength chosen such that it can perform tissue bonding and unite the lips of a wound, and a holding piece suitable for being secured to the tissue around the wound so as to keep the lips of the wound approximated, at least while the wound is being exposed to said laser radiation, the holding piece including at least one region suitable for being positioned over the wound and sufficiently transparent at the wavelength of the laser radiation for the energy from said radiation to be sufficient, after it has passed through said region, to perform the desired tissue bonding.
Type:
Grant
Filed:
July 22, 1999
Date of Patent:
May 13, 2003
Assignee:
Galderma Research & Development, S.N.C.
Inventors:
Serge R. Mordon, Alexandre Capon, Chryslain Sumian
Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
Type:
Grant
Filed:
February 4, 2000
Date of Patent:
October 8, 2002
Assignee:
Galderma Research & Development S.N.C.
Inventors:
Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I):
as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
Abstract: The invention concerns the use of at least one activator of receptors of the PPAR-&ggr; type for preparing a pharmaceutical composition for treating skin disorders related to an anomaly of the differentiation of epidermic cells.
Type:
Grant
Filed:
September 7, 2000
Date of Patent:
June 11, 2002
Assignee:
Galderma Research & Development S.N.C
Inventors:
Michel Rivier, Irina Safonova, Serge Michel
Abstract: The invention relates to novel stilbene compounds having the general formula (I):
as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.
Type:
Grant
Filed:
December 31, 1997
Date of Patent:
April 10, 2001
Assignee:
Galderma Research & Development S.N.C.
Inventors:
Jean-Michel Bernardon, Bruno Charpentier
Abstract: The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma/glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.
Type:
Grant
Filed:
April 14, 1999
Date of Patent:
October 3, 2000
Assignee:
Galderma Research & Development, S.N.C.
Inventors:
Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
Abstract: This invention relates to the use of benzonaphthalene compounds for the treatment of peripheral neuropathies, central neurodegenerative diseases and autoimmune diseases of the nervous system.
Type:
Grant
Filed:
January 8, 1999
Date of Patent:
March 28, 2000
Assignee:
Galderma Research & Development, S.N.C.
Inventors:
Xavier Vige, Jesus Benavides, Braham Shroot, Veronique Taupin
Abstract: Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene present in these cells. The pharmaceutical composition is more particularly intended to treat pathologies chosen from breast cancers, B cell lymphomas, leukaemias, neuroblastomas, adenocarcinomas of the prostate, prolactinomas and other pituitary adenomas.